한글목차

비알코올성 지방간염 치료 시장 규모는 최근 급격하게 확대되고 있습니다. 2025년 35억 7,000만 달러에서 2026년에는 49억 8,000만 달러에 이르고, CAGR 39.6%의 성장이 전망되고 있습니다. 지난 수년간의 성장세는 비만 유병률 증가, 2형 당뇨병 발생률 증가, 가공식품 과다 섭취, 간 건강에 대한 인식 부족, 초기 NASH에 대한 치료 옵션의 제한 등이 원인으로 추정됩니다.

비알코올성 지방간염 치료 시장 규모는 향후 몇 년간 급격한 성장이 전망됩니다. 2030년에는 189억 7,000만 달러에 이르고, CAGR은 39.7%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 정밀의료의 발전, 새로운 NASH 치료제 개발, 디지털 건강 모니터링 도구의 도입, 간질환 예방을 위한 정부 정책, 간질환 연구개발에 대한 투자 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 개인 맞춤형 생활습관 및 식단 관리, 비침습적 진단 기술 발전, 지방간 질환 인식 제고 프로그램, 재택 간 건강 모니터링, 새로운 약리학적 약제 개발 등이 있습니다.

인슐린 저항성 유병률 증가가 비알코올성 지방간염(NASH) 치료제 시장의 성장을 주도하고 있습니다. 인슐린 저항성이란 근육, 지방, 간세포가 인슐린에 효과적으로 반응하지 않아 고혈당을 유발하는 상태를 말합니다. 일반적으로 건강에 해로운 생활습관, 과도한 당분 섭취, 유전적 요인과 관련이 있는 것으로 알려져 있습니다. 인슐린 저항성 증가는 당뇨병 및 기타 간 관련 질환 증가와 관련이 있으며, 이러한 질환은 종종 NASH 치료법으로 해결됩니다. 예를 들어, 2025년 7월 미국 기반 생의학 문헌 데이터베이스 PubMed는 비만, 복부비만, 고도비만, 인슐린 저항성 유병률이 각각 34.9%에서 41.4%, 62.5%에서 67.0%, 5.2%에서 11.5%, 22.5%에서 30.2%로 크게 증가했다고 보고했습니다. 보고했습니다. 그 결과, 간 및 당뇨병 관련 질환으로 인한 인슐린 저항성 유병률 증가가 NASH 치료제 시장을 견인할 것으로 예측됩니다.

비알코올성 지방간염(NASH) 치료제 시장의 주요 기업들은 고객 기반 확대, 매출 증대, 수익 성장 촉진을 위해 내인성 호르몬과 같은 혁신적인 제품에 집중하고 있습니다. 내인성 호르몬은 체내에서 자연적으로 생성되는 물질로 다양한 생리적 기능을 조절하는 역할을 합니다. 예를 들어, 2023년 9월 미국 바이오기업 89바이오(89bio Inc.)는 미국 식품의약국(FDA)으로부터 NASH 진단을 받은 환자를 대상으로 한 페고자페르민(Pegozafermin)에 대해 획기적 치료법 지정(BTD)을 획득했다고 발표했습니다. 발표하였습니다. 페고자펄민은 섬유아세포 성장인자 21(FGF21)의 유전자 변형 글리코 PEG화 유사체입니다. 이 혁신적인 제품은 NASH 및 중증 고중성지방혈증(SHTG)을 대상으로 개발되고 있습니다. 페고자페르민의 글리코 PEG화 기술을 이용하여 효능을 유지하면서 반감기를 연장하고, 중성지방 감소, 혈당 조절, 지방간, 염증, 섬유화 등 주요 인자를 조절하는 능력이 강화되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Non-alcoholic steatohepatitis (NASH) treatment involves approaches such as maintaining a healthy diet, controlling blood sugar, and promoting weight and fat loss. NASH is a liver disease where individuals, who consume little or no alcohol, develop fatty livers, leading to liver cell damage and inflammation. If untreated, this can progress to cirrhosis.

The main drugs used in NASH treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, and others. Vitamin E is a fat-soluble nutrient that helps reduce oxidative stress in liver cells, reducing liver damage and inflammation, while pioglitazone works to improve insulin sensitivity and manage high blood sugar levels, often linked to type 2 diabetes. Diagnostic tests such as blood tests, liver biopsies, and imaging procedures are used to monitor the condition, with treatment distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies.

Tariffs have influenced the non-alcoholic steatohepatitis treatment market by affecting the cost and availability of imported active pharmaceutical ingredients (APIs) and advanced diagnostic equipment. This has increased production costs for drugs like pioglitazone and obeticholic acid, particularly impacting Asia-Pacific suppliers and distributors. Hospital pharmacies and specialty drug segments are most affected, while some domestic manufacturers benefit from protective tariffs by gaining a competitive advantage in local markets.

The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $3.57 billion in 2025 to $4.98 billion in 2026 at a compound annual growth rate (CAGR) of 39.6%. The growth in the historic period can be attributed to rising prevalence of obesity, increasing incidence of type 2 diabetes, high consumption of processed foods, lack of awareness about liver health, limited treatment options for early-stage nash.

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $18.97 billion in 2030 at a compound annual growth rate (CAGR) of 39.7%. The growth in the forecast period can be attributed to advancements in precision medicine, development of novel nash drugs, adoption of digital health monitoring tools, government initiatives for liver disease prevention, increasing investment in liver disease research. Major trends in the forecast period include personalized lifestyle & diet management, non-invasive diagnostic advancements, fatty liver disease awareness programs, home-based liver health monitoring, novel pharmacological agents development.

The increasing prevalence of insulin resistance has driven the growth of the non-alcoholic steatohepatitis (NASH) treatment market. Insulin resistance occurs when cells in muscles, fat, and the liver do not respond effectively to insulin, resulting in high blood sugar levels. It is commonly linked to an unhealthy lifestyle, excessive sugar intake, and genetic factors. The rise in insulin resistance has been associated with an increase in diabetes and other liver-related issues, conditions that are often treated with NASH therapies. For example, in July 2025, PubMed, a U.S.-based biomedical literature database, reported a significant increase in the prevalence of obesity, abdominal obesity, severe obesity, and insulin resistance, with rates rising from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Consequently, the growing prevalence of insulin resistance due to liver and diabetes-related diseases is expected to propel the NASH treatment market.

Major companies in the non-alcoholic steatohepatitis (NASH) treatment market are focusing on innovative products like endogenous hormones to expand their customer bases, increase sales, and drive revenue growth. Endogenous hormones are naturally occurring substances in the body that regulate various physiological functions. For example, in September 2023, 89bio Inc., a U.S.-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin in individuals diagnosed with NASH. Pegozafermin is an engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). This innovative product is being developed for NASH and severe hypertriglyceridemia (SHTG). The use of glycoPEGylated technology in Pegozafermin gives it an extended half-life while preserving its potency, enhancing its ability to modulate key factors such as triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.

In September 2023, Kriya Therapeutics, a U.S.-based biotechnology company focused on gene therapy for metabolic and neurodegenerative diseases, acquired Tramontane Therapeutics for an undisclosed amount. This acquisition enhances Kriya's NASH treatment pipeline by adding a one-time gene therapy program targeting Fibroblast Growth Factor 21 (FGF21), further strengthening its capabilities in metabolic-liver disease therapeutics. Tramontane Therapeutics, a Spain-based biotechnology company, specializes in gene therapy programs for metabolic and neurodegenerative diseases, and its lead candidate for NASH utilizes AAV-mediated FGF21 expression.

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-alcoholic steatohepatitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-alcoholic steatohepatitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Vitamin E And Pioglitazone; Ocaliva; Elafibranor; Selonsertib And cenicriviroc; Obeticholic Acid; Other Drugs Types
• 2) By Test Type: Blood Tests; Liver Biopsy; Imaging Procedures
• 3) By End User: Hospital Pharmacies; Retail And Specialty Pharmacies; Other End Users
• Subsegments:
• 1) By Vitamin E And Pioglitazone: Vitamin E Supplements; Pioglitazone-Based Formulations.
• 2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
• 3) By Elafibranor: Elafibranor Monotherapy; Elafibranor Combination Therapy
• 4) By Selonsertib And Cenicriviroc: Selonsertib Formulations; Cenicriviroc Formulations
• 5) By Obeticholic Acid: Immediate-Release Obeticholic Acid; Extended-Release Obeticholic Acid
• 6) By Other Drug Types: Novel Agents In Clinical Trials; Combination Therapies
• Companies Mentioned: AstraZeneca PLC; Galmed Pharmaceuticals Ltd.; Genfit S.A.; Zydus Cadila Healthcare Limited; Bristol-Myers Squibb Company; Gilead Sciences Inc.; Novo Nordisk A/S; Inventiva Pharma SA; NGM Biopharmaceuticals Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Corporation; Intercept Pharmaceuticals Inc.; Cirius Therapeutics Inc.; Viking Therapeutics Inc.; Eli Lilly and Company; Terns Pharmaceuticals Inc.; AbbVie Inc.; Johnson & Johnson Private Limited; Sanofi S.A.; F. Hoffmann-La Roche Ltd.; C.H. Boehringer Sohn AG & Co. KG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Non-Alcoholic Steatohepatitis Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Non-Alcoholic Steatohepatitis Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Personalized Lifestyle & Diet Management
  • 4.2.2 Non-Invasive Diagnostic Advancements
  • 4.2.3 Fatty Liver Disease Awareness Programs
  • 4.2.4 Home-Based Liver Health Monitoring
  • 4.2.5 Novel Pharmacological Agents Development

5. Non-Alcoholic Steatohepatitis Treatment Market Analysis Of End Use Industries

• 5.1 Hospital Pharmacies
• 5.2 Retail Pharmacies
• 5.3 Specialty Pharmacies
• 5.4 Diagnostic Centers
• 5.5 Research Institutions

6. Non-Alcoholic Steatohepatitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Alcoholic Steatohepatitis Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Non-Alcoholic Steatohepatitis Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Non-Alcoholic Steatohepatitis Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Alcoholic Steatohepatitis Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Alcoholic Steatohepatitis Treatment Market Segmentation

• 9.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
• 9.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Blood Tests, Liver Biopsy, Imaging Procedures
• 9.3. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
• 9.4. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Vitamin E And Pioglitazone, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vitamin E Supplements, Pioglitazone-Based Formulations
• 9.5. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Ocaliva, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ocaliva (Obeticholic Acid) For NASH
• 9.6. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Elafibranor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Elafibranor Monotherapy, Elafibranor Combination Therapy
• 9.7. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Selonsertib And Cenicriviroc, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Selonsertib Formulations, Cenicriviroc Formulations
• 9.8. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Obeticholic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
• 9.9. Global Non-Alcoholic Steatohepatitis Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Novel Agents In Clinical Trials, Combination Therapies

10. Non-Alcoholic Steatohepatitis Treatment Market Regional And Country Analysis

• 10.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market

• 11.1. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Alcoholic Steatohepatitis Treatment Market

• 12.1. China Non-Alcoholic Steatohepatitis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Alcoholic Steatohepatitis Treatment Market

• 13.1. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Alcoholic Steatohepatitis Treatment Market

• 14.1. Japan Non-Alcoholic Steatohepatitis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Alcoholic Steatohepatitis Treatment Market

• 15.1. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Alcoholic Steatohepatitis Treatment Market

• 16.1. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Alcoholic Steatohepatitis Treatment Market

• 17.1. South Korea Non-Alcoholic Steatohepatitis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Alcoholic Steatohepatitis Treatment Market

• 18.1. Taiwan Non-Alcoholic Steatohepatitis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Alcoholic Steatohepatitis Treatment Market

• 19.1. South East Asia Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Alcoholic Steatohepatitis Treatment Market

• 20.1. Western Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Alcoholic Steatohepatitis Treatment Market

• 21.1. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Alcoholic Steatohepatitis Treatment Market

• 22.1. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Alcoholic Steatohepatitis Treatment Market

• 23.1. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Alcoholic Steatohepatitis Treatment Market

• 24.1. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Alcoholic Steatohepatitis Treatment Market

• 25.1. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market

• 26.1. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Alcoholic Steatohepatitis Treatment Market

• 27.1. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Alcoholic Steatohepatitis Treatment Market

• 28.1. North America Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Alcoholic Steatohepatitis Treatment Market

• 29.1. USA Non-Alcoholic Steatohepatitis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Alcoholic Steatohepatitis Treatment Market

• 30.1. Canada Non-Alcoholic Steatohepatitis Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Alcoholic Steatohepatitis Treatment Market

• 31.1. South America Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Alcoholic Steatohepatitis Treatment Market

• 32.1. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Alcoholic Steatohepatitis Treatment Market

• 33.1. Middle East Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Alcoholic Steatohepatitis Treatment Market

• 34.1. Africa Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Alcoholic Steatohepatitis Treatment Market Regulatory and Investment Landscape

36. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape And Company Profiles

• 36.1. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Non-Alcoholic Steatohepatitis Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Non-Alcoholic Steatohepatitis Treatment Market Company Profiles
  • 36.3.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Galmed Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Genfit S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Zydus Cadila Healthcare Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

37. Non-Alcoholic Steatohepatitis Treatment Market Other Major And Innovative Companies

• Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd.

38. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market

40. Non-Alcoholic Steatohepatitis Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Non-Alcoholic Steatohepatitis Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Non-Alcoholic Steatohepatitis Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Non-Alcoholic Steatohepatitis Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer